Dexcom– tag –
-
CNET Names Dexcom Stelo, Abbott FreeStyle Libre 3 Plus, and Eversense 365 as Top Continuous Glucose Monitors for 2026, Setting New Standards in Blood Sugar Management
CNET USA Overview CNET's 2026 review identifies Dexcom Stelo, Abbott FreeStyle Libre 3 Plus, and Eversense 365 as leading continuous glucose monitoring (CGM) devices. These systems excel in sensor life, accuracy, and FDA approval status,... -
Wearable Device ‘Disappearing Act’ Accelerates as Dexcom’s Latest CGM Shrinks by 50%
ZDNET USA Overview Wearable devices are evolving towards 'invisible' designs to integrate more naturally into users' lifestyles, aiming to minimize their presence and enable more consistent wear, thereby enhancing user experience. Dexcom... -
Non-Invasive Blood Sugar Monitoring Faces Accuracy and Reliability Hurdles; True Non-Invasive Devices Remain Undeveloped
Health.com USA Overview While non-invasive blood sugar meters hold promise for finger-prick-free glucose checks, most currently available devices fail to meet the expected medical-grade accuracy and reliability for daily tracking. Many p... -
Diabetes Devices Dominate FDA MAUDE Reports 2020-2025 with Over 50% of Adverse Events, Dexcom Largest Single Reporter
Global MedTech Expert | 10× MedTech Global Access Unknown Overview An analysis of 14.4 million FDA MAUDE adverse event reports from 2020 to 2025 reveals that diabetes-related devices account for over half of all reported events. Continuo... -
Supply Chain Integrity Under Fire: Pharmsource Denies Knowledge of Stolen, Recalled Dexcom G7 Sensors
Investing.com 南アフリカ Overview Pharmaceutical wholesaler Pharmsource LLC denies knowing that Dexcom G7 continuous glucose monitoring (CGM) sensors it acquired were stolen post-disposal and resold, despite being originally slated for d... -
Goodman Advisory Group Invests $1.29 Million in DexCom Amidst Strong Q1 Performance, Revenue Soars 15% to $1.19 Billion
MarketBeat USA Overview Goodman Advisory Group has made a strategic investment of $1.29 million in DexCom, a leading continuous glucose monitoring (CGM) company, following DexCom's strong first-quarter earnings report. The company achiev... -
FDA Clears Dexcom’s Stelo, First Over-the-Counter CGM for Non-Insulin-Using Children Aged Two and Older
FDA USA Overview The U.S. FDA has approved Dexcom's Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM) for children aged two and older who do not use insulin. This expansion significantly ... -
FDA Approves Finger-Prick Free Dexcom Stelo and Abbott Libre CGMs, Revolutionizing Metabolic Management for Non-Insulin Users
Mattioli 1885 / GoodRx USA Overview The FDA has approved continuous glucose monitoring (CGM) systems like Dexcom Stelo and Abbott's Lingo (and FreeStyle Libre series), eliminating the need for traditional finger-prick tests and marking a... -
Dexcom Reaffirms CGM Benefits for All People with Diabetes, Expands to Preventive Care with Stelo App Relaunch and Nutrisense Acquisition at ADA 2026
DexCom, Inc. USA Overview Dexcom announced favorable results from the CONNECT randomized controlled trial at ADA 2026, reaffirming CGM's benefits for non-insulin using type 2 diabetes patients. The company also launched early access to i... -
Dexcom Battles Black Market for Decommissioned CGM Sensors, Warns of Patient Safety Risks
Businesswire (PRF Technologies経由) USA Overview Dexcom, a prominent diabetes technology firm, has disclosed a significant security breach involving the theft and illicit resale of decommissioned continuous glucose monitoring (CGM) senso...
